BNB PLUS CORP.
Close on Oct 19, 2026
- Market cap
- $878.33K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $304.00K | $-34.00 | – |
| Q2 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | $983.00K | $-15.35 | – |
| Q1 FY2025 Ended Dec 31, 2024 | Feb 13, 2025 | After market close | $1.20M | $-0.56 | – |
| Q4 FY2024 Ended Sep 30, 2024 | Dec 17, 2024 | After market close | $813.00K | $-0.32 | – |
| Q3 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | $798.00K | $0.47 | – |
| Q2 FY2024 Ended Mar 31, 2024 | May 10, 2024 | After market close | $930.00K | $-5.31 | – |
| Q1 FY2024 Ended Dec 31, 2023 | Feb 8, 2024 | After market close | $891.00K | $-0.09 | – |
| Q4 FY2023 Ended Sep 30, 2023 | Dec 7, 2023 | After market close | $780.00K | $-0.26 | – |
| Q3 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Mar 31, 2023 | May 11, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Dec 31, 2022 | Feb 9, 2023 | After market close | – | – | – |
| Q4 FY2022 Ended Sep 30, 2022 | Dec 14, 2022 | After market close | – | – | – |
Company guidance
Outlook given with results on Dec 17, 2024, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| operating expense reductions | fiscal 2025 | 15% | New |
| annual revenue capacity | annual | $4.00M to $16.00M | – |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Bnb Plus filed with the SEC
BNB Plus Corp. Announces Strategic Shift to
Regulation FD disclosure · EX-99.1 to Form 8-K
BNB Plus Corp. (BNBX) Announces Nasdaq Delisting
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
BNB Plus Corp. (BNBX) Secures Initial
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
BNB Plus Corp. (BNBX) Appoints James Haft as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Applied DNA Rebrands as BNB
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
DNA Sciences Closes up to $58 Million Private Placement; Announces Initial BNB Holdings Valued at Over $17 Million
Other events · EX-99.1 to Form 8-K
DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Applied DNA Sciences, Inc., a Delaware corporation (the “ Company ”) entered into a securities purchase agreement (the
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
The further development and acceptance of
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
DNA Reports Third Quarter Fiscal 2025
Results of operations · EX-99.1 to Form 8-K
DNA Sharpens Strategic Focus on Synthetic DNA
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Applied DNA Announces Retirement of Chairperson
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
N.Y. – May 29, 2025 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”),
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
DNA Reports Second Quarter Fiscal 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
1-For-50 Reverse Stock Split Effective March 14, 2025
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
DNA Reports First Quarter Fiscal 2025
Results of operations · EX-99.1 to Form 8-K
©2025 Applied DNA Sciences, Inc. Empowering the Genetic Medicines Revolution Nasdaq: APDN January 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Applied DNA Announces Pricing of $6.5 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Applied DNA Regains Compliance with Nasdaq
Other events · EX-99.1 to Form 8-K
Applied DNA Announces Third Quarter Fiscal Year
Results of operations · EX-99.1 to Form 8-K
Applied DNA Announces Pricing of $12 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Applied DNA Announces Second Quarter Fiscal Year
Results of operations · EX-99.1 to Form 8-K
Cell - Free Enzymatic DNA Empowering the Genetic Medicines Revolution Nasdaq: APDN
Regulation FD disclosure · EX-99.1 to Form 8-K
Applied DNA Announces 1-For-20 Reverse Stock
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Applied DNA Announces First Quarter Fiscal Year
Results of operations · EX-99.1 to Form 8-K
Applied DNA Announces $3.44 Million Registered
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
A Next Generation Platform for Genetic Medicine Manufacturing Nasdaq: APDN
Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter Fiscal Year 2023
Results of operations · EX-99.1 to Form 8-K
Applied DNA Reports Third Quarter Fiscal 2023 Financial
Results of operations · EX-99.1 to Form 8-K
DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT TM Platform to Substantially Improve mRNA Manufacturing
Material agreement · Acquisition or disposition completed · Unregistered share sale · Other events · EX-99.1 to Form 8-K
©2023 Applied DNA Sciences, Inc. Applied DNA Acquires Spindle Biotech Better RNA…Faster July 13, 2023 ©2023 Applied DNA Sciences, Inc. Nasdaq: APDN
Material agreement · Acquisition or disposition completed · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
First Quarter Fiscal 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Fiscal Year
Results of operations · EX-99.1 to Form 8-K
Third Quarter Fiscal 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
DNA Announces Pricing of $12 Million Upsized Public Offering,
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Closing of Upsized $12 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
DNA Initiates Analytical Validation of PCR-based
Other events · EX-99.1 to Form 8-K